Developer docs
API playgroundTry for free, no card

Search company profiles

ClostraBio

Full company profile

uuid0000c3l

Namestring
ClostraBio
Legal namestring
ClostraBio, Inc.
Websiteurl
clostrabio.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
probiotic supplements, gut health therapeutics, targeted metabolite delivery, inflammatory bowel disease, nanoparticle drug delivery
Industry3 codes
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements
SECONDARYAFAJAJAE
Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)
NAICS code1 code
  • Food Manufacturing311
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Probiotic & Gut Health Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Probiotic Dietary Supplement Sales (CLB101)
TypeOne Time License
Description

Direct sales of CLB101 probiotic supplement through e-commerce and partner distribution channels (Designs for Health, Maypro) targeting gut health consumers and healthcare practitioners.

clostrabio.com
2Therapeutic Development (CLB-004)
TypeLicensing Royalties
Description

Development of CLB-004 therapeutic asset for IBD (ulcerative colitis) through clinical trials. Intended to be developed as a pharmaceutical product with potential licensing or commercialization.

clostrabio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1CLB101
Description

Next-generation probiotic featuring Anaerostipes caccae CLB101 strain, designed to support gut barrier function, immunity, and balanced gut microbiome by producing butyrate directly in the gut.

clostrabio.com
+2 more records
Core offering1 text field

ClostraBio develops and sells CLB101, a next-generation butyrate-producing probiotic dietary supplement featuring the Anaerostipes caccae CLB101 strain with self-affirmed GRAS status, and is developing CLB-004, a proprietary oral targeted metabolite delivery platform using block copolymer micelles for controlled release of butyrate in the lower gut to treat inflammatory bowel disease (IBD) and food allergies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Clinical study with 48 subjects evaluating CLB101 safety, tolerability, and gut health benefits including intestinal barrier integrity
+1 more record
Product overview1 text field

ClostraBio offers two distinct products: (1) CLB101™, a next-generation probiotic dietary supplement launched commercially in Fall 2025, which delivers butyrate-producing bacteria directly to the gut; and (2) CLB-004, a proprietary therapeutic drug delivery platform using polymeric micelle technology for targeted, extended release of butyrate to treat IBD and food allergy. The company focuses on restoration of intestinal barrier-protective function and innate immunity through metabolite delivery solutions.

Product and service2 records
1CLB101 Probiotic
CategoryProbiotic Dietary Supplement
Description

A next-generation probiotic dietary supplement featuring Anaerostipes caccae CLB101, a butyrate-producing strain isolated from healthy humans. CLB101 supports gut barrier function, immunity, and a balanced gut microbiome by producing butyrate directly in the lower intestine. It has been granted self-affirmed GRAS status and was launched commercially in Fall 2025.

2CLB-004
CategoryTherapeutic Asset / Drug Delivery Platform
Description

A proprietary, oral, targeted metabolite delivery platform using block copolymers that self-assemble into micelles to protect and stabilize butyrate, releasing it enzymatically in the ileum, cecum, and colon. CLB-004 is being developed to treat inflammatory bowel disease (IBD) and food allergy by modulating barrier function and immune response without suppressing immunity. IND-enabling toxicology studies are underway with plans for Phase 1a/b clinical studies in mild-moderate ulcerative colitis.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-12
Description

Partnership to launch CLB101 probiotic in North America. Maypro provides distribution capabilities for the gut health product that produces butyrate directly to support gut barrier integrity.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-24
Description

Strategic collaboration for commercial launch of probiotic product featuring CLB101 strain. Designs for Health, a healthcare practitioner-focused supplement brand, distributes the Anaerostipes Probiotic product targeting gut dysfunction. ClostraBio also conducting clinical study to evaluate safety and gut health benefits.

3Scott Ravech (Board Appointment)
Strategic tierCoreTypeOthersAnnounced on2025-09-17
Description

Industry veteran Scott Ravech appointed to Board of Directors. Ravech has extensive experience in probiotics industry, having led Deerland Probiotics & Enzymes through acquisition by ADM.

clostrabio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct peer developing next-generation probiotics targeting gut health and metabolic conditions, including glucose control. Comparable to ClostraBio in its emphasis on mechanistic, strain-specific probiotic innovation and direct-to-consumer plus practitioner distribution.

TypeDirect peer
Description

Direct peer producing microbially-based consumer probiotics and synbiotics for gut and vaginal health. Comparable to ClostraBio's CLB101 in targeting science-forward consumers with proprietary probiotic strains via DTC and partner channels.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia for IBD and other indications. Most directly comparable to ClostraBio's CLB-004 therapeutic program in mechanism (microbiome-derived therapy) and indication overlap (ulcerative colitis).

TypeDirect peer
Description

Microbiome therapeutics company that developed SER-109 (Vowst) for recurrent C. difficile and is advancing programs in IBD. Closely comparable to ClostraBio's CLB-004 in targeting gut-mediated disease with microbiome-derived approaches.

TypeDirect peer
Description

Direct-to-consumer probiotics and microbiome testing company founded by Dr. Mahmoud Ghannoum targeting gut fungal and bacterial balance. Comparable to ClostraBio in consumer gut-health positioning and probiotic product focus.

TypeDirect peer
Description

Clinical-stage company developing oral microbiome-based therapies for inflammatory diseases. Comparable to ClostraBio's CLB-004 in therapeutic modality (single-strain oral microbiome therapy) and inflammatory disease focus.

TypeBroad incumbent
Description

Large ingredients company that acquired Ganeden (a top-tier probiotic ingredient brand) and supplies probiotic strains to supplement and food manufacturers. Comparable as a broader incumbent in probiotic ingredients competing for the same channel partners and finished-product brand contracts.

TypeBroad incumbent
Description

Global nutrition company that acquired Deerland Probiotics & Enzymes (led by Scott Ravech, now on ClostraBio's board). Comparable as a broad incumbent in probiotic ingredients, supplements, and enzymes competing in the same practitioner and CPG channels.

9BioGaia
TypeBroad incumbent
Description

Established Swedish probiotics company selling clinically documented Lactobacillus and Bifidobacterium strains across consumer and pediatric channels. Comparable as a broad incumbent with proprietary probiotic strains and global distribution.

TypeOthers
Description

Immune-tolerance therapeutics company co-founded by Prof. Jeffrey Hubbell (ClostraBio co-founder), targeting celiac disease and multiple sclerosis using red blood cell-engaging polymers. Thematically comparable as a Hubbell spinout leveraging immunoengineering in adjacent autoimmune indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ClostraBio

Probiotic & Gut Health Therapeuticsclostrabio.com

ClostraBio firmographics

Firmographics
Name
ClostraBio
Legal name
ClostraBio, Inc.
Website
https://clostrabio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ClostraBio industry classification

Industry
Product category
Probiotic & Gut Health Therapeutics
NAICS
Food Manufacturing (311)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements
SECONDARYAFAJAJAE
Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)

Keywords

  • Probiotic supplements
  • Gut health therapeutics
  • Targeted metabolite delivery
  • Inflammatory bowel disease
  • Nanoparticle drug delivery

Where ClostraBio is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ClostraBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations

Revenue model

  1. Probiotic Dietary Supplement Sales (CLB101): Direct sales of CLB101 probiotic supplement through e-commerce and partner distribution channels (Designs for Health, Maypro) targeting gut health consumers and healthcare practitioners.
  2. Therapeutic Development (CLB-004): Development of CLB-004 therapeutic asset for IBD (ulcerative colitis) through clinical trials. Intended to be developed as a pharmaceutical product with potential licensing or commercialization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

ClostraBio product offering

Product offering

Core offering

ClostraBio develops and sells CLB101, a next-generation butyrate-producing probiotic dietary supplement featuring the Anaerostipes caccae CLB101 strain with self-affirmed GRAS status, and is developing CLB-004, a proprietary oral targeted metabolite delivery platform using block copolymer micelles for controlled release of butyrate in the lower gut to treat inflammatory bowel disease (IBD) and food allergies.

Product overview

ClostraBio offers two distinct products: (1) CLB101™, a next-generation probiotic dietary supplement launched commercially in Fall 2025, which delivers butyrate-producing bacteria directly to the gut; and (2) CLB-004, a proprietary therapeutic drug delivery platform using polymeric micelle technology for targeted, extended release of butyrate to treat IBD and food allergy. The company focuses on restoration of intestinal barrier-protective function and innate immunity through metabolite delivery solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • CLB101: Next-generation probiotic featuring Anaerostipes caccae CLB101 strain, designed to support gut barrier function, immunity, and balanced gut microbiome by producing butyrate directly in the gut.
  • CLB-004
  • Anaerostipes Probiotic

Products and services

  • CLB101 Probiotic A next-generation probiotic dietary supplement featuring Anaerostipes caccae CLB101, a butyrate-producing strain isolated from healthy humans. CLB101 supports gut barrier function, immunity, and a balanced gut microbiome by producing butyrate directly in the lower intestine. It has been granted self-affirmed GRAS status and was launched commercially in Fall 2025.
  • CLB-004 A proprietary, oral, targeted metabolite delivery platform using block copolymers that self-assemble into micelles to protect and stabilize butyrate, releasing it enzymatically in the ileum, cecum, and colon. CLB-004 is being developed to treat inflammatory bowel disease (IBD) and food allergy by modulating barrier function and immune response without suppressing immunity. IND-enabling toxicology studies are underway with plans for Phase 1a/b clinical studies in mild-moderate ulcerative colitis.

Quantifiable outcome

  • Clinical study with 48 subjects evaluating CLB101 safety, tolerability, and gut health benefits including intestinal barrier integrity
  • +1 more outcomes

Companies that use ClostraBio

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

ClostraBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ClostraBio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • MayprocoreChannel Partner/ Reseller/ Distributor · 12 November 2025Partnership to launch CLB101 probiotic in North America. Maypro provides distribution capabilities for the gut health product that produces butyrate directly to support gut barrier integrity.
  • Designs for HealthcoreChannel Partner/ Reseller/ Distributor · 24 October 2025Strategic collaboration for commercial launch of probiotic product featuring CLB101 strain. Designs for Health, a healthcare practitioner-focused supplement brand, distributes the Anaerostipes Probiotic product targeting gut dysfunction. ClostraBio also conducting clinical study to evaluate safety and gut health benefits.
  • Scott Ravech (Board Appointment)coreOthers · 17 September 2025Industry veteran Scott Ravech appointed to Board of Directors. Ravech has extensive experience in probiotics industry, having led Deerland Probiotics & Enzymes through acquisition by ADM.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

ClostraBio competitors and assessment

Company assessment

Direct peers

  • Pendulum Therapeutics: Direct peer developing next-generation probiotics targeting gut health and metabolic conditions, including glucose control. Comparable to ClostraBio in its emphasis on mechanistic, strain-specific probiotic innovation and direct-to-consumer plus practitioner distribution.
  • Seed Health: Direct peer producing microbially-based consumer probiotics and synbiotics for gut and vaginal health. Comparable to ClostraBio's CLB101 in targeting science-forward consumers with proprietary probiotic strains via DTC and partner channels.
  • Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for IBD and other indications. Most directly comparable to ClostraBio's CLB-004 therapeutic program in mechanism (microbiome-derived therapy) and indication overlap (ulcerative colitis).
  • Seres Therapeutics: Microbiome therapeutics company that developed SER-109 (Vowst) for recurrent C. difficile and is advancing programs in IBD. Closely comparable to ClostraBio's CLB-004 in targeting gut-mediated disease with microbiome-derived approaches.
  • BIOHM Health: Direct-to-consumer probiotics and microbiome testing company founded by Dr. Mahmoud Ghannoum targeting gut fungal and bacterial balance. Comparable to ClostraBio in consumer gut-health positioning and probiotic product focus.
  • Evelo Biosciences: Clinical-stage company developing oral microbiome-based therapies for inflammatory diseases. Comparable to ClostraBio's CLB-004 in therapeutic modality (single-strain oral microbiome therapy) and inflammatory disease focus.

Broad incumbents

  • Kerry Group (Ganeden): Large ingredients company that acquired Ganeden (a top-tier probiotic ingredient brand) and supplies probiotic strains to supplement and food manufacturers. Comparable as a broader incumbent in probiotic ingredients competing for the same channel partners and finished-product brand contracts.
  • ADM (Deerland Probiotics & Enzymes): Global nutrition company that acquired Deerland Probiotics & Enzymes (led by Scott Ravech, now on ClostraBio's board). Comparable as a broad incumbent in probiotic ingredients, supplements, and enzymes competing in the same practitioner and CPG channels.
  • BioGaia: Established Swedish probiotics company selling clinically documented Lactobacillus and Bifidobacterium strains across consumer and pediatric channels. Comparable as a broad incumbent with proprietary probiotic strains and global distribution.

Others

  • Anokion (Hubbell-founded): Immune-tolerance therapeutics company co-founded by Prof. Jeffrey Hubbell (ClostraBio co-founder), targeting celiac disease and multiple sclerosis using red blood cell-engaging polymers. Thematically comparable as a Hubbell spinout leveraging immunoengineering in adjacent autoimmune indications.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ClostraBio social profiles

Digital presence

ClostraBio compliance and trust

Trust signal

Compliance1 record

ClostraBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ClostraBio leadership team

Management profile

Number of profiles

Profiles13 records

ClostraBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ClostraBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ClostraBio

What does ClostraBio do?

ClostraBio develops and sells CLB101, a next-generation butyrate-producing probiotic dietary supplement featuring the Anaerostipes caccae CLB101 strain with self-affirmed GRAS status, and is developing CLB-004, a proprietary oral targeted metabolite delivery platform using block copolymer micelles for controlled release of butyrate in the lower gut to treat inflammatory bowel disease (IBD) and food allergies.

Is ClostraBio a public or private company?

ClostraBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was ClostraBio founded?

ClostraBio was founded in 2017. It employs 11 to 50 people.

Where is ClostraBio based?

ClostraBio is headquartered in Chicago, United States, in the North America region.

How does ClostraBio make money?

Two revenue lines are on record. Probiotic Dietary Supplement Sales (CLB101) is the primary driver. The others are therapeutic Development (CLB-004).

Who are ClostraBio's main competitors?

Direct peers on record are Pendulum Therapeutics, Seed Health, Vedanta Biosciences, Seres Therapeutics, BIOHM Health and Evelo Biosciences. Broad incumbents are Kerry Group (Ganeden), ADM (Deerland Probiotics & Enzymes) and BioGaia. Anokion (Hubbell-founded) is listed as an others.

Does ClostraBio have an API?

No public API is recorded for ClostraBio.

What industry is ClostraBio in?

ClostraBio's product category is Probiotic & Gut Health Therapeutics. Its primary akta.pro industry code is HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics), with a secondary code of CRADAGAF, Probiotics & Digestive Health Supplements. Its NAICS code is 311 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogClostraBio Announces Positive Results in Landmark Clinical Study with Next-Generation Probiotic CLB101™ and NutraIngredients USA 2026 AwardClostraBio announced positive topline results from the first randomized, double-blind, placebo-controlled human clinical study of its next-generation probiotic strain CLB101™ (Anaerostipes caccae), achieving both the primary safety and tolerability endpoint while demonstrating statistically significant differences in key secondary efficacy endpoints. The study evaluated the butyrate-producing probiotic in a four-week design incorporating subject-reported outcomes based on the validated Gastrointestinal Symptom Rating Scale and multiple exploratory biomarkers. Additionally, the commercialized product Anaerostipes Probiotic, marketed by Designs for Health and containing CLB101™, won "Product of the Year: Microbiome Modulation" at the 2026 NutraIngredients USA Awards.nutraingredients.comNutraWomen Wednesday: Ritu Shah, CEO, ClostraBioClostraBio CEO Ritu Shah discusses her transition into the gut health sector, driven by the potential of butyrate-producing probiotics to address conditions like food allergies and inflammatory bowel disease. She highlights the company's strategy to utilize a distinct regulatory pathway for faster market entry while reflecting on her leadership philosophy and career milestones at companies such as Baxter.nutraingredients.comProbiota Pioneer: ClostraBio on spinning out the single bacterial species abundant in non-allergic individualsClostraBio, a startup spun out of the University of Chicago, is commercializing CLB101, a next-generation probiotic strain derived from healthy individuals to support gut barrier integrity and food tolerance. The company has secured partnerships with Designs for Health for practitioner channel distribution and Maypro for consumer brand ingredient supply, following successful GRAS self-affirmation and early clinical safety trials.nutraingredients.comMeet the 2026 Probiota Pioneers: ClostraBio, Holobiome and KiogaClostraBio, Holobiome, and Kioga have been selected as the 2026 Probiota Pioneers to showcase their microbiome science innovations at the upcoming Probiota Americas conference in Vancouver. ClostraBio is advancing its butyrate-delivery product CLB101 with a global distribution partnership and clinical trials, while Holobiome focuses on precision therapeutics for depression using its extensive microbial genome vault. Kioga is developing postbiotic ingredients targeting stress resilience and neuro-immune balance through its NeuroAlly platform.CBS NewsClostraBio CEO Ritu Shah shares her journey into biotech to inspire others: "Don't let anything stop you."ClostraBio CEO Ritu Shah shared her career journey and advice for women during Women's History Month to inspire others in the biotech sector. The Chicago-based company focuses on developing probiotics for gut health, citing customer testimonials as evidence of their product's efficacy.Business Wire BlogClostraBio and Winners of the Chicago Innovation Awards Ring the Nasdaq Opening BellClostraBio joined Chicago Innovation Awards winners in New York City on August 31 to ring the Nasdaq opening bell. The company's winning innovation is CLB101, a next-generation probiotic that produces butyrate and has achieved GRAS status. The company plans to publish clinical study data after manuscript submission.nutraingredients.comClostraBio and Maypro team up to bring next-gen gut probiotic to marketClostraBio and Maypro have partnered to market the probiotic CLB101 in North America, aimed at supporting gut health through microbiome diversity and gut barrier function. CLB101 is unique in producing butyrate directly in the gut, distinguishing it from other probiotics. The product was launched publicly at the SupplySide Global event and is under clinical study.NutraceuticalsworldMaypro Partners with ClostraBio to Launch CLB101Maypro has entered into an exclusive distribution partnership with ClostraBio to launch CLB101, a next-generation probiotic, in the North American market. The product is highlighted as the first Anaerostipes caccae probiotic available for dietary supplements, designed to support gut barrier integrity and immune function through butyrate production.Longevity.TechnologyDesigns for Health launches CLB101 probiotic with ClostraBio partnershipDesigns for Health, in collaboration with microbiome biotechnology company ClostraBio, has launched a commercial product featuring the next-generation probiotic strain Anaerostipes caccae CLB101™, marking the commercial entry through a practitioner-channel partnership. ClostraBio has simultaneously initiated a 48-subject human clinical study evaluating CLB101™ for safety, tolerability, and exploratory endpoints on gut health and intestinal barrier integrity. The strain has achieved self-affirmed GRAS status as a strict anaerobe capable of producing butyrate in the lower gut, and both companies plan to showcase their progress at the SupplySide Global industry event from October 27-30.